To contentTo navigationTo search

Implantica presents the fourth quarter 2022 on February 17 at 15:00 CET

 | Non regulatory

Implantica AG (publ) invites investors to a presentation of the fourth quarter 2022 at 15:00 CET on February 17. The interim report for the fourth quarter will be published at 8:00 a.m. CET on the same day.

The presentation will be in English via an audiocast with teleconference:

Conference call dial-in:

  • Sweden: +46 8 505 163 86
  • United Kingdom: +44 20 319 84884
  • United States: +1-412-317-6300

Pin code: 2209644#



  • CEO Peter Forsell
  • CFO Andreas Öhrnberg
  • Chief Corporate Affairs Officer Nicole Pehrsson

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB,

The information was sent for publication, through the agency of the contact person set out above, on February 13, 2023 at 09:30 a.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information.